The interaction between methyldopa and levodopa was studied in 18 patients with Parkinsonism. Together they produced a fall in blood pressure in doses which when given alone had no effect or only a slight hypotensive effect. Severe hypotension never occurred. It is reasonable to give methyldopa to hypertensive patients on levodopa but the regimen should be initiated in hospital.
Introduction
Since the introduction of levodopa for the treatment of patients with Parkinsonism a variety of interactions between levodopa and other drugs have been reported (Hunter et al., 1970) .
Theoretically, an interaction between levodopa and methyldopa could be envisaged since methyldopa can cause Parkinsonism by inhibiting decarboxylase, thus preventing the conversion of dopa to dopamine.
Although levodopa has been reported to cause postural hypotension (Barbeau, 1969; Calne, 1969; Calne, 1970; Duvoisin, 1970; McDowell and Lee, 1970 ) the hypotension is not related to the dose. In the past, it has been thought inadvisable to give methyldopa and levodopa together. However, many patients with Parkinsonism have hypertension and are effectively controlled on methyldopa. Fermaglich and O'Doherty (1971) reporting on patients with Parkinsonism who received both drugs found that Parkinsonism was improved by adding methyldopa to levodopa. The average dose of levodopa was reduced from 3-244 g to 0-96 g when methlydopa was added. However, careful assessment of the blood pressure was not made.
In this study the interaction between the two drugs on the blood pressure is investigated.
Westminster Hospital Group, London SWlP 2AP F. B. GIBBERD, M.B., F.R.C.P., Consultant Physician ELIZABETH SMALL, M.B., M.R.C.P., Senior Registrar in Physical Medicine Method Eighteen inpatients with Parkinsonism were investigated as follows. While not receiving treatment, lying and standing blood pressure measurements were recorded at 6 a.m., 11 a.m., 1 p.m., and 3 p.m. The effect of a single dose of 250 mg methyldopa was assessed by administering the drug at 6 a.m. and measuring lying and standing blood pressures at 6 a.m., 11 a.m., 1 p.m., and 3 p.m. The patients were then started on treatment with levodopa until two weeks later, with the patient on a mean dose or 1-5 ± 0 5 g levodopa a further 250 mg of methyldopa was administered and lying and standing pressure again monitored at 6 a.m., 11 p.m., 1 p.m.; and 3 p.m.
Three of the patients were also given methyldopa 250 mg twice a day for one day while on a dose of 1-75-2-5 g levodopa.
Results
Results of the standing blood pressure are shown in the levodopa, third between methyldopa and methyldopa with levodopa and fourth between levodopa and levodopa with methyldopa. These four comparisons were not made simultaneously. There was no effect on lying blood pressure from these drugs either singly or in combination. Methyldopa alone produced a slight fall in standing diastolic blood pressure, levodopa and methyldopa together produced a fall in standing systolic and standing diastolic blood pressure. The three patients on the higher dose of levodopa (mean dose 2 g) who received 500 mg methyldopa showed the same blood pressure changes as before.
Discussion
Our trial did not confirm the findings of Calne (1970) who found that with levodopa alone a fall occurred in the mean systolic pressure of 19-3 mm Hg when standing. However, we did not use maximally tolerated doses of the drug.
The hypotensive effect of these two drugs in combination is likely to be that of potentiation rather than synergism but too few patients were studied to be certain of this. In Fermaglich and O'Doherty's (1971) investigation no change in the blood pressure was noted but special studies of the blood pressure would be needed in order to show slight change. Hunter et al. (1970) found that for a hypertensive patient on guanthidine the dose of this drug had to be substantially reduced if the patient was put on levodopa. The results show that methyldopa and levodopa together lowered the blood pressure in doses which, given singly, did not affect it significantly.
Parkinsonism was unaffected by the administration of methyldopa, but our patients were given the drug for only a few days. There are reports, however, of Parkinsonism induced by methyldopa (Peaston, 1964; Vaidya et al., 1970) in people who had no Parkinsonism symptoms before they took methyldopa. In another report by Groden (1963) Parkinsonism returned to a patient when he was given methyldopa, his previous Parkinsonism having occurred when on reserpine. Methyldopa crosses the blood brain barrier in animals and therefore theoretically it could be interacting with levodopa in the extrapyramidal system. Levodopa like methyldopa may produce a state of autoimmunity with a positive Coombs test (Cotzias, 1969) , but no cases of haemolytic anaemia have been reported. In our series haemolytic anaemia did not occur, although a Coombs test was not done regularly.
It is reasonable to consider giving methyldopa to hypertensive patients on levodopa. This should be attempted only in a hospital, where the blood pressure can be carefully monitored and the dosage of the drug slowly increased.
